Fused deposition modelling (FDM) is the most commonly investigated 3D printing technology for the manufacture of personalized medicines, however, the high temperatures used in the process limit its wider application. The objective of this study was to print low-melting and thermolabile drugs by reducing the FDM printing temperature. Two immediate release polymers, Kollidon VA64 and Kollidon 12PF were investigated as potential candidates for low-temperature FDM printing. Ramipril was used as the model low melting temperature drug (109°C); to the authors' knowledge this is the lowest melting point drug investigated to date by FDM printing. Filaments loaded with 3% drug were obtained by hot melt extrusion at 70°C and ramipril printlets with a dose equivalent of 8.8 mg were printed at 90°C. HPLC analysis confirmed that the drug was stable with no signs of degradation and dissolution studies revealed that drug release from the printlets reached 100% within 20-30 min. Variable temperature Raman and solid state nuclear magnetic resonance (SSNMR) spectroscopy techniques were used to evaluate drug stability over the processing temperature range. These data indicated that ramipril did not undergo degradation below its melting point (which is above the processing temperature range: 70-90°C) but it was transformed into the impurity diketopiperazine upon exposure to temperatures higher than its melting point. The use of the excipients Kollidon VA64 and Kollidon 12PF in FDM was further validated by printing with the drug 4-aminosalicylic acid (4-ASA), which in previous work was reported to undergo degradation in FDM printing, but here it was found to be stable. This work demonstrates that the selection and use of new excipients can overcome one of the major disadvantages in FDM printing, drug degradation due to thermal heating, making this technology suitable for drugs with lower melting temperatures.
Introduction
3D printing techniques have come a long way since their inception in the early '90s, when they were developed for rapid and economic production of prototype models (Sachs et al., 1993) , to their extensive application in biomanufacturing (Chia and Wu, 2015) and pharmaceuticals (Alomari et al., 2015; Trenfield et al., 2018) . The importance and relevance of 3D printing technologies for pharmaceutical applications have been extensively discussed elsewhere Goole and Amighi, 2016; Palo et al., 2017; Zema et al., 2017) as an enabling technology to produce patient-tailored medicines , to engineer drug release profiles from a dosage form (Fina et al., 2017 (Fina et al., , 2018 Goyanes et al., 2015d; Martinez et al., 2017; Wang et al., 2016) and to deliver multiple drugs (Khaled et al., 2015b (Khaled et al., , 2015a .
Fused deposition modelling (FDM) is the most commonly evaluated 3D printing technique in the pharmaceutical sciences owing to the use of relatively straightforward and less-expensive equipment, diverse choice of excipients and ease of producing dosage forms, even with complex geometries, which have good patient acceptability (Goyanes et al., 2015c (Goyanes et al., , 2017b Schiele et al., 2013) . The FDM process involves heating and extruding a drug loaded polymer strand (prepared beforehand by hot melt extrusion) through a nozzle tip followed by solidification onto a build plate into the desired geometry. One potential issue with this type of printing, therefore, is the high temperature the drugs might be exposed to during material extrusion and printing (Goyanes et al., 2015a (Goyanes et al., , 2016a . In a previous study we reported that thermal degradation of 4-aminosalicylic acid during FDM printing reached 50%, emphasising the need for lowering the processing temperatures for thermally labile drugs (Goyanes et al., 2015a) .
The majority of the existing literature on pharmaceutical applications of FDM involve printing temperatures in the range of 150-230°C, primarily using polyvinyl alcohol (PVA), polylactic acid (PLA), hydroxypropyl cellulose (HPC), other cellulose derivatives and various grades of Eudragit polymers (RL, RS and E), since these polymers extrude and print well (Alhijjaj et al., 2016; Genina et al., 2017; Gioumouxouzis et al., 2017; Goyanes et al., 2014 Goyanes et al., , 2015b Goyanes et al., , 2018 Goyanes et al., , 2017a Goyanes et al., , 2016b Goyanes et al., , 2015c Melocchi et al., 2015 Melocchi et al., , 2016 Muwaffak et al., 2017; Okwuosa et al., 2017; Pietrzak et al., 2015; Sadia et al., 2016; Skowyra et al., 2015; Solanki et al., 2018; Zhang et al., 2017a Zhang et al., , 2017b . However, most of these polymers, excluding Eudragit E and HPC, are not well suited for formulation of immediate release dosage forms, which account for approximately 70% of oral dosage formulations . There are limited studies investigating immediate release 3D printed formulations, using PVP and Eudragit EPO, that print at relatively lower temperatures in the range of 110-135°C Sadia et al., 2016) . There is therefore a need to develop polymer filaments that (i) extrude and print at lower temperatures so as to enable 3D printing of thermolabile drugs and (ii) that are suitable for immediate release formulations.
Reports on the use of Kollidon VA64 and Kollidon 12PF in association with the plasticizer -PEG 1500 on the suitability of polymers for hot melt extrusion throws light on these polymer-plasticizer combinations, as potential candidates for exploring possible filament compositions that could be printed at significantly lower temperatures (Karl et al., 2010) . Kollidon VA64 is a water soluble vinylpyrrollidone-vinyl acetate copolymer, widely used in pharmaceutical formulations as a direct compression, film-forming and taste-masking excipient and is known for its suitability in hot-melt extrusion processes. Kollidon 12PF is a low molecular grade polyvinylpyrrolidone commonly used as a solubilising agent and crystallization inhibitor.
A drug that could benefit from advances in lower printing temperatures is ramipril, an angiotensin converting enzyme (ACE) inhibitor antihypertensive agent, normally used in combination with other drugs in the treatment of multitude of cardiovascular indications. Ramipril has a melting point of 109°C and requires dose flexibility. It is available in fixed dosage strengths, ranging between 1.25 mg and 20 mg with an initial dose of 1.25 or 2.5 mg, and it needs adjustment depending on blood potassium levels and concurrent administration of diuretics (Warner and Perry, 2002) .
The objective of the present work was to explore the use of Kollidon VA64 and Kollidon 12PF as suitable excipients to prepare immediate release formulations lowering the printing temperature of the FDM 3D printing process in order to accommodate thermolabile and lowmelting temperature drugs. Printlets (3D printed tablets) incorporating a therapeutically relevant dose of ramipril (selected as a model drug) were prepared by FDM printing. Moreover, a secondary aim of the study was to apply this new knowledge to the printing of 4-aminosalicylic acid (4-ASA), a drug which we have shown previously to degrade under standard FDM printing conditions (Goyanes et al., 2015a) .
Material and methods
Ramipril (RMP) was purchased from Baoji Guokang Bio Technology Co Ltd (Baoji, China). Kollidon VA64 (vinylpyrrolidone-vinyl acetate copolymers) and Kollidon 12PF (polyvinylpyrrolidone) were obtained from BASF (Germany), PEG 1500 and magnesium carbonate were purchased from Sigma Aldrich (UK), Mannitol was purchased from Alfa Aesar (UK), formic acid and analytical grades of acetonitrile and methanol, and 4-aminosalicylic acid (4-ASA) were purchased from VWR International Ltd., (UK).
Preparation of drug-loaded ramipril filaments
Kollidon VA 64, PEG 1500, mannitol, ramipril and magnesium carbonate (65%, 20%, 10%, 3% and 2% w/w respectively) were manually mixed using a mortar and pestle ( Table 1) . The mixture was then extruded using a single-screw extruder (Noztek Pro filament extruder, NozteK, UK) at 70°C through a nozzle with diameter 1.3 mm at screw speed of 15 rpm. The resulting filament was stored in a vacuum desiccator before printing. Ramipril loading in the filaments was determined by HPLC analysis. Filaments were also formulated by replacing 50% and 40% of Kollidon VA64 from the above formulation with Kollidon 12PF (Table 1) .
3D printing of ramipril dosage forms
Dosage forms were fabricated with the drug-loaded filament using a standard fused-deposition modelling 3D printer, MakerBot Replicator 2X Desktop (MakerBot Inc., USA). The template used to print the dosage form was designed with AutoCAD 2014 (Autodesk Inc., USA) and exported as a stereolithography (.stl) file into MakerWare v. 2.4.1 (MakerBot Inc., USA). The selected geometry of the dosage forms was a flat faced cylindrical tablet with dimensions, X = 10 mm, Y = 10 mm and Z = 3.6 mm. The infill percentage was 100% in order to produce solid dosage forms of high density and other printer settings were as follows: standard resolution with the raft option deactivated and an extrusion temperature of 90°C, speed while extruding (90 mm/s), speed while traveling (150 mm/s), number of shells (2) and layer height (0.20 mm).
Morphology
The physical dimensions of the printlets were measured using a digital Vernier caliper. Pictures of the devices were taken with a Nikon Coolpix S6150 with the macro option of the menu.
Determination of the mechanical properties of the printlets
The printlet breaking force of 6 printlets of each type was measured using a traditional tablet hardness tester TBH 200 (Erweka GmbH, Heusenstamm, Germany), whereby an increasing force is applied perpendicular to the tablet axis to opposite sides of a tablet until the printlet fractures.
X-ray powder diffraction (XRPD)
X-ray powder diffraction data were obtained using Cu-Kα (λ = 1.5418 Å) radiation with a Philips PANalytical X'Pert MPD Pro diffractometer (with PW3064 sample spinner and PANalytical Data Collector) operating at 40 kV. X-ray measurements were collected over a 2θ range of 5-40°with a step size of 0.007°and scan step time of 60 s. The resulting diffractograms were analysed using PANalytical High Score plus against the standard references from the Cambridge structural database.
Thermal analysis
Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were used to characterise the melting point and degradation profile of the drug. DSC measurements were performed with a Q2000 DSC (TA Instruments, Waters, LLC, U.S.A.) at a heating rate of 10°C/min. Calibration for cell constant and enthalpy was performed with indium (Tm = 156.6°C, ΔHf = 28.71 J/g) according to the manufacturer instructions. Nitrogen was used as a purge gas with a flow rate of 50 mL/min for all the experiments. Data were collected with TA Advantage software for Q series (version 2.8.394), and analysed using TA Instruments Universal Analysis 2000. Melting temperature is reported as extrapolated onset unless otherwise stated. TA aluminium pans and lids (Tzero) were used with an average sample mass of 8-10 mg. For TGA analysis, samples were heated at 10°C/min in open aluminium pans with a Discovery TGA (TA Instruments, Waters, LLC, U.S.A.). Nitrogen was used as a purge gas with a flow rate of 25 mL/ min. Data collection and analysis were performed using TA Instruments Trios software and percent mass loss or onset temperature were calculated.
Determination of drug loading
A printlet or a section of drug-loaded strand (approximately 1 g) was placed in a volumetric flask with deionized water (1 L) under magnetic stirring until complete dissolution (n = 3). Samples of the solutions were then filtered through 0.45 μm filter (Millipore Ltd., Ireland) and the concentration of drug determined with HPLC (HewlettPackard 1050 Series HPLC system, Agilent Technologies, U.K.).
The validated high performance liquid chromatographic assay entailed, injecting 5 μL samples for analysis using a mobile phase, consisting of isocratic system of aqueous phase (10%) composed of 0.1% formic acid and organic phase (90%) composed of methanol and acetonitrile (15:85) pumped at a flow rate of 1 mL/min, through a Luna 5 μm C18 column, 150 × 4.6 mm (Phenomenex, U.K.) maintained at 40°C. The eluent was screened at a wavelength of 210 nm. The assay method for ramipril was proven to be discriminatory for the impurity rampiril diketopiperazine (impurity D), anticipated inactive degradant of ramipril. Impurity D was prepared as per the method given by Amjad Anwwari et al. (2008) . Retention times of ramipril and the impurity D were found to be 2.4 and 6.1 min respectively. All measurements were made in duplicate.
Dissolution testing
Dissolution profiles were obtained using a USP-II apparatus (Model PTWS, Pharmatest, Germany). In each assay, the printlets were placed at the bottom of the vessel in 0.1 N HCl pH 1.2, (750 mL) under constant paddle stirring (50 rpm) at 37°C. During the dissolution test, samples of ramipril were automatically removed and filtered through 10 µm filters and drug concentration was determined using an in-line UV spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) operated at the wavelength of maximum absorbance of the drug in 0.1 N HCl (210 nm). Data were processed using Icalis software (Icalis Data Systems Ltd., Berkshire, UK). Tests were conducted in triplicate under sink conditions. Data are reported throughout as mean ± standard deviation.
Raman spectroscopy
Raman spectroscopy was carried out using a LabRAM HR Evolution (HORIBA UK Ltd.) in a backscatter configuration with 532 nm excitation (laser power 499 mW), and an acquisition time of 10 s for 3 accumulations. Spectra were collected using a 50× objective at a 4 cm −1 resolution, over scan ranges of 50-3400 cm −1 using 600 g/mm grating. For the spectra collected in z-axis, 100× objective was used with a step size of 1 µm. Variable temperature experiments were conducted using a hot stage associated with the spectrometer. Samples were heated at 10°C/min and held for 5 min at specific temperature while spectra were collected.
Solid state nuclear magnetic resonance (SSNMR) spectroscopy
Solid-state NMR data were acquired on a Bruker Avance III HD wide bore NMR spectrometer operating at a static magnetic field strength of B 0 = 9.4 T. Powdered or granular samples of Ramipril, Ramipril diketopiperazine, extruded filament, and a physical mixture of the compounds comprising the extruded filament were packed into 4 mm o.d. zirconia rotors with either Kel-F or zirconia caps. Carbon-13 NMR spectra were acquired under magic angle spinning (MAS) conditions using a Bruker 4 mm triple resonance (X/Y/ 1 H) MAS probe operating in double resonance mode. Spectra were acquired at 13 C and 1 H Larmor frequencies of ν0 = 100.6 and 400.1 MHz, respectively, and processed using TopSpin version 3.5pl7. NMR spectra were acquired at temperatures between 20 and 90°C. The sample temperature in variable temperature NMR experiments was controlled with a BVTB 3500 temperature control unit operated via the TopSpin software. The heating rate was limited to a maximum of 5°C/min. Carbon-13 NMR spectra were collected using a cross polarization (CP) pulse sequence with total suppression of spinning sidebands (TOSS) (Antzutkin, 1999; Song et al., 1993) . Proton 90°pulses were 3 μs in length, and 13 C 90 and 180°pulses were 4 and 8 μs in length, respectively. Samples were spun at MAS rates of 6 or 12 kHz. Proton decoupling at a frequency of 83 kHz was carried out using the SPINAL64 (Fung et al., 2000) decoupling sequence. Proton T 1 values were determined using the saturation recovery pulse sequence and recycle delays were an optimized 1.3 * T 1 for each sample at each temperature except where short recycle delays were prohibited by the duty cycle. Recycle delays varied from 3.5 to 5 s for Ramipril, 3.5 s for Ramipril diketopiperazine, and were 10 s for the filament and the physical mixture of compounds. Contact times in CP experiments were optimized for bulk crystalline Ramipril and were 2 ms. The number of transients obtained for the 13 C NMR spectra of Ramipril and Ramipril diketopiperazine ranged from 243 to 1944; 7290 transients were averaged for the 13 C NMR spectra of the filament and physical mixture of compounds. Carbon-13 chemical shift values were referenced to TMS at δ = 0 ppm by adjusting the field such that the methylene peak in the 13 C NMR spectrum of solid adamantane resonated at δ iso = 38.48 ppm (Morcombe and Zilm, 2003) . For all 13 C NMR spectra, 10 Hz of line broadening was applied before processing.
Sample temperatures under MAS conditions were calibrated using 207 Pb NMR spectra of solid powdered lead (II) nitrate (Bielecki and Burum, 1995; Takahashi et al., 1999) . The temperature at ambient conditions was determined using a sample of neat methanol (Ammann et al., 1982) . Lead-207 NMR data were acquired using single-pulse experiments with a 4 μs 90°pulse at a Larmor frequency of 83.4 MHz. The recycle delay and number of transients in 207 Pb NMR spectra were 60 s and 16 transients, respectively. Plots of NMR spectra were prepared for publication with DMFit (Massiot et al., 2002) .
3D printing of 4-aminosalicylic acid (4-ASA) printlets and HPLC determination
A filament of Kollidon VA 64, PEG 1500, mannitol, 4-ASA and magnesium carbonate (65%, 20%, 10%, 3% and 2% w/w respectively) was prepared as in Section 2.1. Printlets of 4-ASA prepared with Kollidon VA 64 filament were fabricated as in Section 2.2 under the same conditions. 4-ASA loading in the printlets was determined by HPLC analysis as reported in Section 2.7. For 4-ASA, the HPLC method involved injecting 10 μL samples for analysis using a mobile phase, consisting of isocratic system of aqueous phase (76%) composed of 0.1% orthophosphoric acid and organic phase (24%) composed of acetonitrile pumped at a flow rate of 1 mL/min through a Discovery HSF5 column (4.6 × 150 mm) maintained at 40°C. The eluent was screened at a wavelength of 303 nm, all measurements were made in duplicate.
Results and discussion
Ramipril printlets were successfully printed at 90°C by FDM 3D for all the formulations listed in the Table 1 (Fig. 1) . The printlets produced were white and showed good uniformity in physical dimensions, with a mean thickness of 3.62 ± 0.05 mm, diameter of 10.54 ± 0.04 mm, and weight of 294.5 ± 3 mg.
All the formulations showed appropriate properties for handling and were mechanically strong. The printlet breaking force data show values close to 485 N that represent the maximum force measurable by the tablet hardness tester. These values are comparable to those previously reported from printlets prepared using polyvinyl alcohol (PVA) (Goyanes et al., 2015a) .
The immediate release polymers Kollidon VA 64 and Kollidon 12PF were found to be viable excipients for printing at temperatures below 100°C. Initially ramipril loaded filaments were produced using Kollidon VA64 alone as the polymer without any Kollidon 12PF, in combination with PEG 1500 as a primary plasticizer, mannitol, and magnesium carbonate as a stabilising agent. Mannitol was added as a secondary plasticizer to produce filaments with sufficient flexibility for printing and additionally for its pore former capacity, since mannitol has been also reported to work as a channelling agent in 3D printed formulations (Beck et al., 2017) . Magnesium carbonate is a pharmaceutically accepted excipient, which has been reported to have a stabilizing effect on ACE inhibitors in a formulation by providing an alkaline environment that protects the active ingredient from oxidation, hydrolysis and cyclization (Harris et al., 1988) , and is also known for its application in high temperature insulating compositions (Farrar, 1994 ). Numerous formulations were tested with varying polymer and plasticizer combinations (data not shown) in order to achieve filaments that could be produced at lower temperatures and that also had a good balance between flexibility and tensile strength so as to avoid collapsing and breaking during printing. The first selected formulation (VA64 from Table 1 ) was processed by hot melt extrusion at 75°C to obtain the filament, which was used to print the cylindrical printlets (Fig. 1) at 90°C. A die with a diameter of 1.3 mm was used for extruding the 1.75 mm diameter filaments required for printing, due to polymer expansion after exiting the nozzle of the extruder.
It is of utmost importance to demonstrate the stability of ramipril during the extrusion and printing steps, considering its susceptibility to a range of factors such as mechanical stress, heat, moisture and excipients (Shafiq and Shakeel, 2008) . DSC and TGA data used to determine the melting point and degradation profile of the drug indicate that ramipril has a melting point of 109°C (Fig. 2) , the drug with the lowest melting temperature printed by FDM so far to the authors' knowledge, which highlights the need for printing the drug at lower temperatures. Although the loss mass in the TGA is not observed until higher temperatures (130°C), below the melting point the drug is not stable and transforms into ramipril diketopiperazine (impurity D) (Amjad Anwwari et al., 2008) .
Chemical integrity of the drug in the final printlets and drug-loaded filaments was analysed using HPLC; the drug loading of the filaments was 3.03 wt% ± 0.04 (theoretical loading -3 wt%) and in the printlets was 8.83 ± 0.14 mg (theoretical amount -8.9 mg), indicating no drug degradation. The stability of the drug over the processing temperature range was further confirmed using variable temperature Raman and SSNMR studies. Ramipril was analysed using a Raman spectrometer equipped with a hot stage microscope over a temperature range between 20°C and 109°C (melting point). The sample was analysed for any degradation by evaluating the Raman spectra collected, at room temperature, at 70°C (the extrusion temperature) and at 90°C (the printing temperature) (Fig. 3) .
The drug is exposed to a specific temperature for a longer time during the extrusion than during the printing process. Taking this into consideration ramipril was held at 70°C for 30 min and at 90°C for 5 min on a hot stage microscope, emulating longer exposure times to the temperatures during the extrusion and printing steps. It is evident from the micrographs (Fig. 4) and the spectral data (Fig. 3 ) that ramipril did not undergo any degradation under these temperatures. Hence, ramipril is expected to be stable in the formulations, which are composed of 97% excipients, thereby exhibiting an additional insulating effect on the drug.
The significance of printing ramipril at lower temperatures is further explained by studying the behaviour of ramipril melt during the cooling cycle. Ramipril was allowed to completely melt by heating the hot-stage to 109°C and spectra were collected at different intervals during the cooling cycle of the melt. It was observed that the Raman spectra of the cooled material are different from that of crystalline ramipril. Splitting of the peak corresponding to the C]O functional group (in conjugation with the primary amide) observed in the frequency Fig. 1 . Pictures of ramipril printlets, from left to right: VA64, VA64:12PF (3:2) and VA64:PF12 (1:1).
Fig. 2. DSC and TGA plots of ramipril.
G. Kollamaram et al. International Journal of Pharmaceutics 545 (2018) 144-152 region of 1635-1665 cm −1 and the absence of the peak corresponding to the O-H functional group in the frequency region of 3200-3400 cm −1 were identified as the predominant differences in the cooled melt and ramipril as received (Fig. 5 ). This can be explained by the possibility of degradation of ramipril to its impurity D during melting. Studies suggest that rampiril diketopiperazine (impurity D) can be synthesised by heating ramipril to 120°C for up to 6-8 h (Amjad Anwwari et al., 2008) and the Raman spectra of impurity D synthesised by this method (Fig. 7) was similar to that of the cooled melt of the ramipril (Fig. 6 ). The absence of the carboxylic hydroxyl group and the presence of di-ketone (primary amide) functionality in the impurity D, further corroborate the differences observed in the Raman spectra of the ramipril collected, before and after melting. This emphasises the need for processing ramipril at lower temperatures. These results also show the potential of Raman spectroscopy as an in-line tool to monitor process induced transitions even at low drug concentration (3% in this case). In line monitoring would require pre formulation experiments to prepare calibration curves and the application of chemometrics to analyse the Raman data, however demonstrations with 2D printed formulations have been already reported using different drugs (Edinger et al., 2017) . Variable temperature SSNMR was used to support the results obtained from Raman spectroscopy. The SSNMR spectra of ramipril collected at temperatures used for extrusion and printing, were similar to that of the ramipril at room temperature except the broadening of the peaks observed in the chemical shift region 120-140 ppm (Fig. 8) , which possibly could be due to the molecular vibrations at higher temperatures. The spectrum collected after cooling the sample back to the room temperature (Fig. 8) further corroborates the stable nature of ramipril over processing temperature range. XRPD and SSNMR were used to examine the solid state of the active ingredient in the final formulations. X-ray diffractograms of the pure components of the formulation were examined and the peaks corresponding to 2θ°-7.6 and 8.11, were identified as the drug peaks without any interference from the excipient (Fig. 9) . The physical mixture of the formulation shows tiny peaks in this region indicating the crystalline nature of the drug but the powdered printlet does not show any peaks suggesting that, either the drug is in its amorphous form in the final formulation or the percentage of the drug is beyond the limit detection of the technique. Similar results were observed with SSNMR (Fig. 10) where the physical mixture showed the presence of crystalline ramipril but the powdered printlet did not show any such signs, which again could possibly due to the amorphous nature of ramipril.
Having confirmed the applicability of Kollidon VA64 for FDM printing at lower temperature, additional filaments were also produced by replacing Kollidon VA64 entirely with Kollidon 12PF, while maintaining the rest of the formulation components constant. The extrusion process of this formulation was much smoother and efficient with an extrusion temperature of 65°C, which was lower than that used for Kollidon VA64. However these filaments were very brittle and not suitable for the subsequent printing steps. This could possibly be due to the lower molecular weight of the Kollidon 12PF which does not facilitate long range interlinking of the polymer chains, essential for the tensile strength of the filament. Taking into account the flexibility in filaments and ease of extrusion achieved using Kollidon VA64 and Kollidon 12PF respectively, filaments were produced using formulations where Kollidon VA64 was partly replaced by Kollidon 12PF (VA64:12PF in the ratios 3:2 and 1:1 as shown in Table 1 ). This resulted in production of filaments at a temperature of 65°C, which were suitable for printing at 90°C. XRPD and HPLC results of these formulations were similar to that of the formulation VA64, showing drug stability during the printing process (data not shown).
Dissolution studies of all three formulations were performed in 0.1 N HCl, simulating gastric conditions, as they were formulated with the objective of producing immediate release dosage forms. As the polymers themselves are water soluble and with the low molecular weight water soluble components in the formulations acting as a pore formers, 100% drug release was achieved within 20-30 min (Fig. 11) . Formulations containing Kollidon 12PF were observed to have faster drug release than Kollidon VA64 alone. This pattern is explained considering the extensive application of Kollidon 12PF as a solubility enhancer in pharmaceutical applications. Based on these observations, the mechanism of drug release from these Kollidon based FDM products could be explained mainly by erosion.
A previous study showed that 4-ASA when printed at temperatures generally used for FDM was degraded to approximately half its initial dose (Goyanes et al., 2015a) . To emphasise the significance of lowering the printing temperature in FDM and as an indicator that the selection of the appropriate formulation composition could avoid drug degradation while printing, 4-ASA printlets were produced based on the Fig. 9 . X-ray powder diffractograms of pure components, physical mixture before printing and powdered printlet of the three formulations. formulation Kollidon VA64. The 4-ASA loaded Kollidon VA64 filaments were extruded at 75°C and printed at 90°C. The evaluation of the drug content using HPLC showed a drug loading of the filaments of 2.91 wt % ± 0.02 (theoretical loading -3 wt%) and the amount of drug in the final printlets was 9.28 ± 0.06 mg (theoretical amount -9.01 mg). These results suggest that the drug did not undergo any degradation either during extrusion or printing, thereby validating the significance of selecting polymers that print at lower temperatures.
Conclusion
Manufacture of printlets of ramipril, a drug with a low melting point (109°C), has been successfully demonstrated by FDM printing at 90°C. The polymer Kollidon VA64 alone or in combination with Kollidon 12PF produced immediate release printlets with no signs of drug degradation. The mixed polymer printlets showed slightly faster drug release compared with those formulated with Kollidon VA64 alone. The applicability of these formulations to prepare low-melting temperature and thermolabile medicines by FDM printing has been shown also with the drug 4-ASA, which in a previous study showed that when printed at temperatures normally used for FDM printing was degraded to approximately half its initial dose. This work demonstrates that the selection and use of new excipients can overcome one of the major obstacles in FDM printing, drug degradation due to thermal heating, making this technology suitable for drugs with lower melting temperatures.
